During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Lonza and Celladon, a biotechnology firm specializing in cardiovascular gene therapy, have entered an agreement that could elevate a multiyear clinical manufacturing contract for Celladon’s Mydicar ...
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback